补气活血软肝煎治疗慢性乙型肝炎肝纤维化的临床观察

Clinical observation on Buqi Huoxue Ruangan decoction in the treatment of chronic hepatitis B hepatic fibrosis

目的探讨补气活血软肝煎对慢性乙型肝炎肝纤维化的临床疗效。方法将60例慢性乙型病毒性肝炎肝纤维化患者随机分为两组。对照组30例予常规保肝药加恩替卡韦分散片治疗,治疗组30例在对照组治疗基础上联合补气活血软肝煎治疗。治疗12周后观察疗效。观察治疗前后的肝功能变化、肝纤维化指标(LN、HA、Ⅳ-C、PC-Ⅲ)、肝硬度检测值(LSM)、门静脉内径以及脾脏大小的变化。结果两组ALT、AST均明显下降(P<0.05),但治疗组下降更为明显(P<0.01),与治疗前相比较,两组HA、LN、Ⅳ-C、PC-Ⅲ、LSM、脾脏厚度均明显下降或缩小(P<0.05),但治疗组下降更为明显(P<0.05);治疗组门静脉内径明显减小(P<0.05),而对照组无变化(P>0.05)。结论补气活血软肝煎可显著改善慢性乙型病毒性肝炎肝纤维化。

Objective To evaluate the clinical efficacy of Buqi Huoxue Ruangan decoction on liver fibrosis in chronic hepatitis B patients. Methods 60 patients with chronic hepatitis B virus liver fibrosis were randomly divided into two groups. 30 cases in the control group were treated with conventional hepatoproteetive garnitavir dispersible tablets. 30 cases of the treatment group were treated with Buqi Huoxue Ruangan decoction on the basis of the treatment of the control group. The efficacy after 12 weeks was observed. The changes of liver function, liver fibrosis index（LN、HA、Ⅳ-C、PC-Ⅲ）, liver stiffness measurement（LSM）, portal vein diameter and spleen size were observed before and after treat- ment. Results ALT and AST were significantly decreased in both groups（P〈0.05）, but the ALT and AST of the treatment group decreased more significantly（P〈0.01）. The levels of HA,LN,Ⅳ-C,PC-Ⅲ,LSM and spleen thickness in the two groups were significantly lower than those before treatment（P〈0.05）, while the treatment group decreased more significantly（P〈0.05）. The portal vein diameter of the treatment group was significantly decreased（P〈0.05）, while the control group had no change（P〉0.05）. Conclusion Buqi Huoxue Ruangan decoction can significantly improve liver fibrosis in chronic hepatitis B virus.